KCM
REGN icon

Kingdon Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kingdon Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,901
Closed -$714K – 62
2019
Q4 		$714K Sell
1,901
-60,564
-97% -$20.4M 0.11% 51
2019
Q3 		$17.3M Buy
62,465
+21,594
+53% +$6.39M 2.05% 16
2019
Q2 		$12.8M Buy
+40,871
New +$13.6M 1.26% 26

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kingdon Capital Management's REGN Position: Q1 2020 in Review

Kingdon Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 1,901 shares — an estimated $714K sold.

Kingdon Capital Management first reported a position in REGN in Q2 2019 and held it in 3 quarters. The position peaked at $17.3M in Q3 2019. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

  • Kingdon Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Kingdon Capital Management sold 1,901 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $714K.
  • Kingdon Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Kingdon Capital Management's Regeneron Pharmaceuticals position peaked at $17.3M in Q3 2019.
  • 816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Kingdon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.